Wichniak A, Jarkiewicz M, Okruszek Ł, Wierzbicka A, Holka-Pokorska J, Rybakowski J K
Third Department of Psychiatry, Institute of Psychiatry and Neurology, Warsaw, Poland.
Department of Neuropsychology, Faculty of Psychology, University of Warsaw, Warsaw, Poland.
Pharmacopsychiatry. 2015 May;48(3):83-8. doi: 10.1055/s-0034-1396802. Epub 2015 Jan 19.
Sleep-promoting antidepressants are of interest because they are used not only as antidepressants, but also to promote sleep.
We reviewed case reports describing the switch to mania during treatment with trazodone, mirtazapine, or agomelatine.
Trazodone, mirtazapine, and agomelatine may induce manic symptoms. However, the risk of switching is related, first of all, to doses recommended for antidepressant treatment, administered without mood-stabilizer co-therapy. Low doses of these antidepressants, used for their hypnotic or sedative effects, were observed to cause mania only in patients with other risk factors for switching. There is no evidence for trazodone or mirtazapine and only sparse evidence for agomelatine, claiming that treatment with these antidepressants is related to an increased risk of switching to mania when administered in combination with a mood stabilizer.
These findings suggest that low doses of trazodone and mirtazapine are safe in bipolar disorder, and should still be considered important alternatives to hypnotics when long-term pharmacological treatment of insomnia is necessary. It seems that these antidepressants and agomelatine can also be used safely in antidepressant doses when combined with a mood stabilizer.
促睡眠抗抑郁药备受关注,因为它们不仅用作抗抑郁药,还用于促进睡眠。
我们回顾了描述在使用曲唑酮、米氮平或阿戈美拉汀治疗期间转为躁狂的病例报告。
曲唑酮、米氮平及阿戈美拉汀可能诱发躁狂症状。然而,转为躁狂的风险首先与抗抑郁治疗推荐剂量相关,且在无心境稳定剂联合治疗的情况下使用。观察发现,低剂量使用这些抗抑郁药以发挥其催眠或镇静作用时,仅在具有其他转为躁狂风险因素的患者中导致躁狂。没有证据表明曲唑酮或米氮平会导致这种情况,而关于阿戈美拉汀仅有少量证据表明,与心境稳定剂联合使用这些抗抑郁药会增加转为躁狂的风险。
这些发现表明,低剂量的曲唑酮和米氮平在双相情感障碍中是安全的,并且在需要对失眠进行长期药物治疗时,仍应被视为催眠药的重要替代药物。似乎这些抗抑郁药和阿戈美拉汀与心境稳定剂联合使用时,以抗抑郁剂量使用也可安全。